Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 19/20 | 0.79 |
| ▸ | JAK1 | P23458 | 2/20 | 0.66 |
| ▸ | JAK2 | O60674 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22229065 | 1.00 | TYK2 (0.79) | TYK2JAK1JAK2CYP3A4CYP2C19 | |
| SCHEMBL22229062 | 1.00 | TYK2 (0.79) | TYK2JAK1JAK2CYP3A4CYP2C19 | |
| SCHEMBL22252376 | 1.00 | TYK2 (0.79) | TYK2JAK1JAK2CYP3A4CYP2C19 | |
| SCHEMBL22229005 | 0.89 | TYK2 (1.00) | TYK2 | |
| SCHEMBL18143581 | 0.88 | TYK2 (1.00) | TYK2 | |
| SCHEMBL16812376 | 0.88 | TYK2 (1.00) | TYK2 | |
| SCHEMBL22229053 | 0.88 | TYK2 (0.80) | TYK2 | |
| SCHEMBL22252606 | 0.88 | TYK2 (0.80) | TYK2 | |
| SCHEMBL22272905 | 0.88 | TYK2 (0.80) | TYK2 | |
| SCHEMBL22229013 | 0.88 | TYK2 (0.80) | TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078125-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-03-19 | — | — | US | disclosed |
| US-12338242-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-24 | — | — | US | disclosed |
| US-20220073528-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-10 | — | — | US | disclosed |
| EP-3914357-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| US-11174264-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2020154474-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20200231594-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174264-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TYK2 1/4885JAK1 3/4885JAK2 2/4885 |
| US-20220073528-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885JAK1 3/4885JAK2 2/4885 |
| US-20260078125-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK3 | TYK2 1/4885JAK1 4/4885JAK2 2/4885 |
| US-20200231594-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885JAK1 3/4885JAK2 2/4885 |
| US-12338242-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TYK2 1/4885JAK1 3/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.